CN1254475C - 用作腺苷受体拮抗剂的5-甲氧基-8-芳基-[1,2,4]三唑并[1,5-a]吡啶衍生物 - Google Patents
用作腺苷受体拮抗剂的5-甲氧基-8-芳基-[1,2,4]三唑并[1,5-a]吡啶衍生物 Download PDFInfo
- Publication number
- CN1254475C CN1254475C CNB028199138A CN02819913A CN1254475C CN 1254475 C CN1254475 C CN 1254475C CN B028199138 A CNB028199138 A CN B028199138A CN 02819913 A CN02819913 A CN 02819913A CN 1254475 C CN1254475 C CN 1254475C
- Authority
- CN
- China
- Prior art keywords
- compound
- methoxy
- formula
- phenyl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01123949.8 | 2001-10-08 | ||
| EP01123949 | 2001-10-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1564821A CN1564821A (zh) | 2005-01-12 |
| CN1254475C true CN1254475C (zh) | 2006-05-03 |
Family
ID=8178877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028199138A Expired - Fee Related CN1254475C (zh) | 2001-10-08 | 2002-09-28 | 用作腺苷受体拮抗剂的5-甲氧基-8-芳基-[1,2,4]三唑并[1,5-a]吡啶衍生物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6693116B2 (enExample) |
| EP (1) | EP1436292B1 (enExample) |
| JP (1) | JP4101756B2 (enExample) |
| KR (1) | KR100604407B1 (enExample) |
| CN (1) | CN1254475C (enExample) |
| AR (1) | AR036735A1 (enExample) |
| AT (1) | ATE338043T1 (enExample) |
| AU (1) | AU2002338827B2 (enExample) |
| BR (1) | BR0213177A (enExample) |
| CA (1) | CA2462801A1 (enExample) |
| DE (1) | DE60214408T2 (enExample) |
| ES (1) | ES2269772T3 (enExample) |
| MX (1) | MXPA04003278A (enExample) |
| PL (1) | PL370565A1 (enExample) |
| RU (1) | RU2298009C2 (enExample) |
| WO (1) | WO2003031445A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1830978B (zh) * | 2005-03-07 | 2010-06-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用 |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2288260A4 (en) * | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| EP2296475A4 (en) | 2008-06-20 | 2014-03-05 | Genentech Inc | TRIAZOLOPYRIDINE COMPOUNDS JAK KINASE INHIBITORS AND METHODS |
| BRPI0922452A2 (pt) * | 2008-12-19 | 2015-12-15 | Leo Pharma As | composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos. |
| CA2763900A1 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| WO2014009425A1 (en) * | 2012-07-12 | 2014-01-16 | Chiesi Farmaceutici S.P.A. | Inhibition of enzymes |
| KR102120190B1 (ko) * | 2012-09-14 | 2020-06-08 | 다우 아그로사이언시즈 엘엘씨 | 4-아미노-2,5-디메톡시피리미딘으로부터의 2-아미노-5,8-디메톡시[1,2,4]트리아졸로[1,5-c]피리미딘의 개선된 제조 방법 |
| SG11201601707PA (en) | 2013-09-05 | 2016-04-28 | Hoffmann La Roche | Triazolopyridine compounds, compositions and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE287262C (enExample) * | ||||
| US6355653B1 (en) | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
-
2002
- 2002-09-18 US US10/246,551 patent/US6693116B2/en not_active Expired - Fee Related
- 2002-09-28 RU RU2004114277/04A patent/RU2298009C2/ru not_active IP Right Cessation
- 2002-09-28 PL PL02370565A patent/PL370565A1/xx not_active Application Discontinuation
- 2002-09-28 ES ES02777254T patent/ES2269772T3/es not_active Expired - Lifetime
- 2002-09-28 CN CNB028199138A patent/CN1254475C/zh not_active Expired - Fee Related
- 2002-09-28 EP EP02777254A patent/EP1436292B1/en not_active Expired - Lifetime
- 2002-09-28 WO PCT/EP2002/010917 patent/WO2003031445A1/en not_active Ceased
- 2002-09-28 DE DE60214408T patent/DE60214408T2/de not_active Expired - Fee Related
- 2002-09-28 AT AT02777254T patent/ATE338043T1/de not_active IP Right Cessation
- 2002-09-28 CA CA002462801A patent/CA2462801A1/en not_active Abandoned
- 2002-09-28 AU AU2002338827A patent/AU2002338827B2/en not_active Ceased
- 2002-09-28 MX MXPA04003278A patent/MXPA04003278A/es active IP Right Grant
- 2002-09-28 KR KR1020047005097A patent/KR100604407B1/ko not_active Expired - Fee Related
- 2002-09-28 JP JP2003534428A patent/JP4101756B2/ja not_active Expired - Fee Related
- 2002-09-28 BR BR0213177-3A patent/BR0213177A/pt not_active IP Right Cessation
- 2002-10-04 AR ARP020103750A patent/AR036735A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US6693116B2 (en) | 2004-02-17 |
| CA2462801A1 (en) | 2003-04-17 |
| KR100604407B1 (ko) | 2006-07-25 |
| DE60214408T2 (de) | 2007-03-08 |
| MXPA04003278A (es) | 2004-07-23 |
| EP1436292B1 (en) | 2006-08-30 |
| ES2269772T3 (es) | 2007-04-01 |
| BR0213177A (pt) | 2004-09-14 |
| US20030134873A1 (en) | 2003-07-17 |
| AU2002338827B2 (en) | 2007-09-06 |
| CN1564821A (zh) | 2005-01-12 |
| KR20040044196A (ko) | 2004-05-27 |
| ATE338043T1 (de) | 2006-09-15 |
| AR036735A1 (es) | 2004-09-29 |
| EP1436292A1 (en) | 2004-07-14 |
| RU2298009C2 (ru) | 2007-04-27 |
| JP4101756B2 (ja) | 2008-06-18 |
| JP2005508954A (ja) | 2005-04-07 |
| DE60214408D1 (de) | 2006-10-12 |
| RU2004114277A (ru) | 2006-01-10 |
| PL370565A1 (en) | 2005-05-30 |
| WO2003031445A1 (en) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1264840C (zh) | 8-甲氧基-(1,2,4)三唑并(1,5-a)吡啶衍生物及其作为腺苷受体配体的应用 | |
| CN100346792C (zh) | 用作腺苷受体配体的苯并噻唑衍生物 | |
| CN1325052C (zh) | 苯并噻唑衍生物 | |
| CN1254475C (zh) | 用作腺苷受体拮抗剂的5-甲氧基-8-芳基-[1,2,4]三唑并[1,5-a]吡啶衍生物 | |
| CN1956983B (zh) | 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺 | |
| CN1257160C (zh) | 氨基喹啉衍生物和它们的作为腺苷a3配体的应用 | |
| CN1564686A (zh) | 8-氨基-[1,2,4]三唑并[1,5-a]吡啶-6-甲酰胺 | |
| CN1304383C (zh) | 苯并噻唑衍生物 | |
| AU2002338827A1 (en) | Adenosine Receptor Ligands | |
| EP1587799B1 (en) | Benzoxazole derivatives and their use as adenosine receptor ligands | |
| KR100765566B1 (ko) | 벤조티아졸 유도체 및 아데노신 a2a 수용체와 관련된질병의 치료에서의 이들의 용도 | |
| CN1791405A (zh) | 苯并噻唑衍生物及其在治疗涉及腺苷a 2a受体的疾病中的应用 | |
| CN1989117B (zh) | 取代的苯并噻唑 | |
| CN1296368C (zh) | 用作腺苷受体调节剂的苯并噻吩化合物 | |
| AU2004203909B8 (en) | Benzoxazol Derivatives | |
| HK1093021A (en) | Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060503 Termination date: 20091028 |